Detalhe da pesquisa
1.
Cutting Edge: Unconventional CD8+ T Cell Recognition of a Naturally Occurring HLA-A*02:01-Restricted 20mer Epitope.
J Immunol
; 208(8): 1851-1856, 2022 04 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35379743
2.
A broad and systematic approach to identify B cell malignancy-targeting TCRs for multi-antigen-based T cell therapy.
Mol Ther
; 30(2): 564-578, 2022 02 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34371177
3.
Simultaneous Deletion of Endogenous TCRαß for TCR Gene Therapy Creates an Improved and Safe Cellular Therapeutic.
Mol Ther
; 28(1): 64-74, 2020 01 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31636040
4.
Preclinical Strategies to Identify Off-Target Toxicity of High-Affinity TCRs.
Mol Ther
; 26(5): 1206-1214, 2018 05 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29567312
5.
Self-sufficient primary natural killer cells engineered to express T cell receptors and interleukin-15 exhibit improved effector function and persistence.
Front Immunol
; 15: 1368290, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38690288
6.
Inhibition of SUMOylation enhances DNA hypomethylating drug efficacy to reduce outgrowth of hematopoietic malignancies.
Leukemia
; 37(4): 864-876, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36792656
7.
Broadly applicable TCR-based therapy for multiple myeloma targeting the immunoglobulin J chain.
J Hematol Oncol
; 16(1): 16, 2023 02 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-36850001
8.
A library of cancer testis specific T cell receptors for T cell receptor gene therapy.
Mol Ther Oncolytics
; 28: 1-14, 2023 Mar 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-36589698
9.
PRAME and CTCFL-reactive TCRs for the treatment of ovarian cancer.
Front Immunol
; 14: 1121973, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37026005
10.
Erratum: A library of cancer testis specific T cell receptors for T cell receptor gene therapy.
Mol Ther Oncolytics
; 31: 100738, 2023 Dec 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-37920174
11.
Comparing CAR and TCR engineered T cell performance as a function of tumor cell exposure.
Oncoimmunology
; 11(1): 2033528, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35127255
12.
T cell receptor engineering of primary NK cells to therapeutically target tumors and tumor immune evasion.
J Immunother Cancer
; 10(3)2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35288464
13.
SARS-CoV-2-specific CD4+ and CD8+ T cell responses can originate from cross-reactive CMV-specific T cells.
Elife
; 112022 11 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-36408799
14.
WT1-specific TCRs directed against newly identified peptides install antitumor reactivity against acute myeloid leukemia and ovarian carcinoma.
J Immunother Cancer
; 10(6)2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35728869
15.
Combining BCMA-targeting CAR T cells with TCR-engineered T-cell therapy to prevent immune escape of multiple myeloma.
Blood Adv
; 7(20): 6178-6183, 2023 10 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-37567150